These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 6682989)

  • 1. Apomorphine response and subtyping of schizophrenia.
    Jeste DV; Zalcman S; Weinberger DR; Cutler NR; Bigelow LB; Kleinman JE; Rogol A; Wyatt RJ
    Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(1):83-8. PubMed ID: 6682989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fenfluramine and chronic schizophrenia.
    Shore D; Korpi ER; Bigelow LB; Zec RF; Wyatt RJ
    Biol Psychiatry; 1985 Mar; 20(3):349-52. PubMed ID: 3884057
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug-induced parkinsonism in schizophrenic patients: motor response and psychiatric changes after acute challenge with L-Dopa and apomorphine.
    Merello M; Starkstein S; Petracca G; Cataneo EA; Manes F; Leiguarda R
    Clin Neuropharmacol; 1996 Oct; 19(5):439-43. PubMed ID: 8889287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lateral ventricular enlargement associated with persistent unemployment and negative symptoms in both schizophrenia and bipolar disorder.
    Pearlson GD; Garbacz DJ; Breakey WR; Ahn HS; DePaulo JR
    Psychiatry Res; 1984 May; 12(1):1-9. PubMed ID: 6589656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Schizophrenic symptoms improve with apomorphine.
    Tamminga CA; Schaffer MH; Smith RC; Davis JM
    Science; 1978 May; 200(4341):567-8. PubMed ID: 347574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses.
    Levy MI; Davis BM; Mohs RC; Kendler KS; Mathé AA; Trigos G; Horvath TB; Davis KL
    Arch Gen Psychiatry; 1984 May; 41(5):520-4. PubMed ID: 6372737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apomorphine and psychopathology.
    Lal S; De la Vega CE
    J Neurol Neurosurg Psychiatry; 1975 Jul; 38(7):722-6. PubMed ID: 1099172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of apomorphine on schizophrenic symptoms.
    Smith RC; Tamminga C; Davis JM
    J Neural Transm; 1977; 40(2):171-6. PubMed ID: 323423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of intravenous and subcutaneous administration of apomorphine on the clinical symptoms of chronic schizophrenics.
    Syvälahti EK; Säkö E; Scheinin M; Pihlajamäki K; Hietala J
    Br J Psychiatry; 1986 Feb; 148():204-8. PubMed ID: 3516291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical effects of apomorphine in schizophrenia.
    Ferrier IN; Johnstone EC; Crow TJ
    Br J Psychiatry; 1984 Apr; 144():341-8. PubMed ID: 6372924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lateral ventricular enlargement and clinical response in schizophrenia.
    Smith RC; Baumgartner R; Ravichandran GK; Mauldin M; Burd A; Vroulis G; Gordon J; Calderon M
    Psychiatry Res; 1985 Mar; 14(3):241-53. PubMed ID: 3858896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The BPRS in assessing symptom correlates of cerebral ventricular enlargement in acute and chronic schizophrenia.
    Bishop RJ; Golden CJ; MacInnes WD; Chu CC; Ruedrich SL; Wilson J
    Psychiatry Res; 1983 Jul; 9(3):225-31. PubMed ID: 6604928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computed tomographic study of aged schizophrenic patients.
    Seno H; Shibata M; Fujimoto A; Kuroda H; Kanno H; Ishino H
    Psychiatry Clin Neurosci; 1997 Dec; 51(6):373-7. PubMed ID: 9472121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of dopamine agonists in the treatment of schizophrenia.
    Corsini GU; Pitzalis GF; Bernardi F; Bocchetta A; Del Zompo M
    Neuropharmacology; 1981 Dec; 20(12B):1309-13. PubMed ID: 7033816
    [No Abstract]   [Full Text] [Related]  

  • 15. Apomorphine's antipsychotic activity.
    Schaffer MH; Davis JM; Tamminga CA
    Arch Gen Psychiatry; 1985 Sep; 42(9):927-8. PubMed ID: 2864035
    [No Abstract]   [Full Text] [Related]  

  • 16. Ventricle-to-brain ratio in schizophrenia: a controlled follow-up study.
    Kemali D; Maj M; Galderisi S; Milici N; Salvati A
    Biol Psychiatry; 1989 Nov; 26(7):756-9. PubMed ID: 2804198
    [No Abstract]   [Full Text] [Related]  

  • 17. A magnetic resonance study of early schizophrenia.
    Johnstone EC; Crow TJ; Macmillan JF; Owens DG; Bydder GM; Steiner RE
    J Neurol Neurosurg Psychiatry; 1986 Feb; 49(2):136-9. PubMed ID: 2869111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lithium addition to neuroleptic treatment in chronic schizophrenia: a randomized, double-blind, placebo-controlled, cross-over study.
    Terao T; Oga T; Nozaki S; Ohta A; Ohtsubo Y; Yamamoto S; Zamami M; Okada M
    Acta Psychiatr Scand; 1995 Sep; 92(3):220-4. PubMed ID: 7484202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical correlates of body weight changes in schizophrenia.
    Lawson WB; Karson CN
    J Neuropsychiatry Clin Neurosci; 1994; 6(2):187-8. PubMed ID: 8044044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computed tomography scans and negative symptoms in schizophrenia: chronic schizophrenics with negative symptoms and nonenlarged lateral ventricles.
    Serban G; George A; Siegel S; DeLeon M; Gaffney M
    Acta Psychiatr Scand; 1990 May; 81(5):441-7. PubMed ID: 2356766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.